A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 70 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant
- Trial Type
- Supportive
- Last Update
- 2 months ago
- SparkCures ID
- 1539
- NCT Identifier
- NCT05732961
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.